JPMorgan Chase & Co. Reduces Holdings in Natus Medical Incorporated (BABY)

JPMorgan Chase & Co. reduced its position in Natus Medical Incorporated (NASDAQ:BABY) by 62.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,310 shares of the medical equipment provider’s stock after selling 56,558 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.10% of Natus Medical worth $1,242,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Eagle Asset Management Inc. grew its position in Natus Medical by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 420,206 shares of the medical equipment provider’s stock valued at $15,673,000 after acquiring an additional 1,268 shares in the last quarter. Principal Financial Group Inc. grew its position in Natus Medical by 0.7% in the 2nd quarter. Principal Financial Group Inc. now owns 252,496 shares of the medical equipment provider’s stock valued at $9,418,000 after acquiring an additional 1,879 shares in the last quarter. Mirador Capital Partners LP grew its position in Natus Medical by 57.0% in the 2nd quarter. Mirador Capital Partners LP now owns 48,552 shares of the medical equipment provider’s stock valued at $1,694,000 after acquiring an additional 17,618 shares in the last quarter. Prudential Financial Inc. grew its position in Natus Medical by 162.0% in the 2nd quarter. Prudential Financial Inc. now owns 225,031 shares of the medical equipment provider’s stock valued at $8,393,000 after acquiring an additional 139,130 shares in the last quarter. Finally, Bridge City Capital LLC acquired a new position in Natus Medical in the 2nd quarter valued at about $1,884,000. 92.66% of the stock is owned by institutional investors.

In other news, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the transaction, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now owns 30,410 shares in the company, valued at $1,036,981. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several equities analysts have weighed in on the company. BidaskClub raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $48.00.

ILLEGAL ACTIVITY WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/10/19/jpmorgan-chase-co-reduces-holdings-in-natus-medical-incorporated-baby.html.

Natus Medical Incorporated (NASDAQ BABY) opened at 39.65 on Thursday. The firm has a market capitalization of $1.29 billion, a P/E ratio of 68.72 and a beta of 0.95. The firm has a 50-day moving average price of $36.77 and a 200 day moving average price of $36.08. Natus Medical Incorporated has a 52-week low of $31.65 and a 52-week high of $43.85.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. The company had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS. Analysts forecast that Natus Medical Incorporated will post $1.70 EPS for the current year.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply